Skip to main content
. 2020 Feb 28;9(2):1108–1112. doi: 10.4103/jfmpc.jfmpc_922_19

Table 3.

Adverse drug reactions monitoring

ADR Control group Study group
HEADACHE 2 1
NAUSEA 3 2
VOMITING 1 1
MYALGIA 2 2